These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34885078)

  • 21. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
    Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapies for the Treatment of Uveal Melanoma-History and Future.
    Schank TE; Hassel JC
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31344957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
    Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
    Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
    Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving Management of Stage IV Melanoma.
    Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uveal melanoma: In the era of new treatments.
    Wespiser M; Neidhardt E; Negrier S
    Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
    Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
    Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
    Klabusay M; Bábková B
    Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
    Tomsitz D; Ruf T; Heppt M; Staeger R; Ramelyte E; Dummer R; Garzarolli M; Meier F; Meier E; Richly H; Gromke T; Siveke JT; Franklin C; Klespe KC; Mauch C; Kilian T; Seegräber M; Schilling B; French LE; Berking C; Heinzerling L
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
    Fu Y; Xiao W; Mao Y
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
    Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
    Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment.
    de Melo AC; Lucena E; de Oliveira DCM; Viola JPB
    Oncologist; 2024 Aug; 29(8):e1098-e1099. PubMed ID: 38785402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.
    Dian Y; Liu Y; Zeng F; Sun Y; Deng G
    Hum Vaccin Immunother; 2024 Dec; 20(1):2374647. PubMed ID: 39004419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
    J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GP100 expression is variable in intensity in melanoma.
    Mann JE; Hasson N; Su DG; Adeniran AJ; Smalley KSM; Djureinovic D; Jilaveanu LB; Schoenfeld DA; Kluger HM
    Cancer Immunol Immunother; 2024 Aug; 73(10):191. PubMed ID: 39105816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Approaches to the Systemic Management of Uveal Melanoma.
    Khan S; Carvajal RD
    Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates in the Management of Uveal Melanoma.
    Barbi M; Carvajal RD; Devoe CE
    Cancer J; 2024 Mar-Apr 01; 30(2):92-101. PubMed ID: 38527262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma.
    Strobel SB; Machiraju D; Hassel JC
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
    Synoradzki KJ; Paduszyńska N; Solnik M; Toro MD; Bilmin K; Bylina E; Rutkowski P; Yousef YA; Bucolo C; Zweifel SA; Reibaldi M; Fiedorowicz M; Czarnecka AM
    Curr Oncol; 2024 Feb; 31(2):778-800. PubMed ID: 38392052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.